Complete Renal Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Benlysta approved for adult patients with active lupus nephritis in Europe 2 The indication of Benlysta (belimumab) was extended after it significantly improved renal outcomes in those with active lupus nephritis. The European Commission (EC) has approved the expanded use of intravenous (IV) and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN), in addition to systemic lupus erythematosus (SLE). Dr Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline (developer of...

EC clears GSK's Benlysta for lupus nephritis 6th May 2021 The European Commission approved expanded use of GlaxoSmithKline’s intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis (LN). The drug is already on the market to treat systemic lupus erythematosus (SLE); this latest approval now provides physicians and patients in Europe with the first and only biologic treatment specifically designed to work in lupus and LN. “Active lupus nephritis, which causes inflammation in the kidneys, is one of th...

FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US Approval builds on nearly 10 years of experience in lupus News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE), the most c...